Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Net revenues			$ 54,220	$ 22,771
Cost of revenues (excluding amortization of acquired intangible assets)			14,989	16,016
Direct expenses			38,326	40,166
Segment contribution			905	(33,411)
Other general and administrative expenses			37,703	40,876
Indirect expenses			1,560	118,001
Loss from operations			(38,358)	(192,287)
Other expenses			(19,534)	(3,998)
Loss before income taxes			(57,892)	(196,285)
Change in fair value of contingent consideration liability			(193)	(104,339)
Goodwill impairment				112,347
IPR&D impairment				107,800
Amortization			1,753	2,193
Total other			1,560	118,001
Cell Therapy [Member]
Segment Reporting Information [Line Items]
Net revenues			688
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses			15,807	28,694
Segment contribution			(15,119)	(28,694)
Goodwill impairment	$ 82,714	$ 29,633
Biobanking [Member]
Segment Reporting Information [Line Items]
Net revenues			5,140	5,441
Cost of revenues (excluding amortization of acquired intangible assets)			1,172	1,650
Direct expenses			1,673	1,752
Segment contribution			2,295	2,039
Degenerative Disease [Member]
Segment Reporting Information [Line Items]
Net revenues			48,392	17,330
Cost of revenues (excluding amortization of acquired intangible assets)			13,817	14,366
Direct expenses			20,846	9,720
Segment contribution			$ 13,729	$ (6,756)